# Korean Post-marketing Surveillance for Xeljanz XR

> **NCT04876781** · — · RECRUITING · sponsor: **Pfizer** · enrollment: 200 (estimated)

## Conditions studied

- Active Moderate to Severe Rheumatoid Arthritis
- Active Ankylosing Spondylitis
- Active Psoriatic Arthritis

## Interventions

- **DRUG:** Tofacitinib XR

## Key facts

- **NCT ID:** NCT04876781
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-12
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876781, "Korean Post-marketing Surveillance for Xeljanz XR". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04876781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*